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Abstract 
Background: The 5 hydroxymethylation (5hmC) mark and TET DNA dioxygenases play a pivotal role in embryonic 
stem cell differentiation and animal development. However, very little is known about TET enzymes in lineage deter-
mination of human bone marrow-derived mesenchymal stem/stromal cells (BMSC). We examined the function of all 
three TET DNA dioxygenases, responsible for DNA hydroxymethylation, in human BMSC cell osteogenic and adipo-
genic differentiation.
Results: We used siRNA knockdown and retroviral mediated enforced expression of TET molecules and discovered 
TET1 to be a repressor of both osteogenesis and adipogenesis. TET1 was found to recruit the co-repressor proteins, 
SIN3A and the histone lysine methyltransferase, EZH2 to osteogenic genes. Conversely, TET2 was found to be a pro-
moter of both osteogenesis and adipogenesis. The data showed that TET2 was directly responsible for 5hmC levels 
on osteogenic and adipogenic lineage-associated genes, whereas TET1 also played a role in this process. Interestingly, 
TET3 showed no functional effect in BMSC osteo-/adipogenic differentiation. Finally, in a mouse model of ovariec-
tomy-induced osteoporosis, the numbers of clonogenic BMSC were dramatically diminished corresponding to lower 
trabecular bone volume and reduced levels of TET1, TET2 and 5hmC.
Conclusion: The present study has discovered an epigenetic mechanism mediated through changes in DNA 
hydroxymethylation status regulating the activation of key genes involved in the lineage determination of skeletal 
stem cells, which may have implications in BMSC function during normal bone regulation. Targeting TET molecules or 
their downstream targets may offer new therapeutic strategies to help prevent bone loss and repair following trauma 
or disease.
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Introduction
DNA methylation and hydroxymethylation have been 
shown to regulate stem cell maintenance and differen-
tiation via the activation or suppression of pluripotency 
and lineage-specific gene expression [1]. Although DNA 
methylation was one of the first epigenetic modifications 
studied, 5 hydroxymethylation has only recently been 
identified as an intermediate step in the process of DNA 
demethylation. Rao and colleagues [2] were the first to 
describe that ten-eleven translocation-1 (TET1) proteins 
can catalyse conversion of 5 methylcytosine (5mC) into 5 
hydroxymethylcytosine (5hmC), as an intermediate step 
to the removal of the methylation mark on DNA, where 
5hmC opposes the repressive effects of 5mC and can 
prevent methylation of DNA [2]. The TET protein fam-
ily are comprised of 2-oxoglutarate and iron-dependent 
dioxygenases, where TET1 is mainly expressed by ESC, 
while TET2 and TET3 are more ubiquitously expressed 
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across different cell lineages [2, 3]. ESC studies have 
shown that a key event in differentiation is the repression 
of pluripotency factors such as Oct4 and Nanog partly 
by DNA methylation [4]. TET1-deficient ESC display 
impaired self-renewal, diminished proliferation, with 
reduced Nanog expression coinciding with increased 
DNA methylation of its promoter [5]. Hematopoietic 
stem cells (HSC) derived from conditional TET2 knock-
out mice display an enhanced ability to reconstitute hae-
matopoiesis in  vivo but prevent HSC from undergoing 
differentiation, providing evidence that TET2 restricts 
aberrant self-renewal and expansion of hematopoietic 
stem cells (HSC) [6]. In support of this notion, one of 
the most common mutations in myeloid malignancies 
is present in TET2, where TET2-deficient HSC show a 
skewed differentiation towards myeloid lineages at the 
expense of lymphoid lineages [7, 8]. Recent studies of 
global TET1 and conditional TET2 knockout mice in 
the mesenchyme lineage showed impaired bone-form-
ing capacity in BMSC [9]. In other systems, conditional 
knockout of TET2 in smooth muscle demonstrated that 
TET2 is essential for smooth muscle cell differentiation 
and that loss of TET2 expression results in de-differenti-
ation [10]. Other studies reported that TET1 and TET2 
mediate Foxp3 demethylation to drive regulatory T cell 
differentiation [11]. A combined loss of TET1 and TET2 
results in depleted 5hmC levels [12], with most mice 
exhibiting midgestation defects and perinatal lethality. 
Triple knockouts of TET1/TET2/TET3 display a com-
plete loss of 5hmC and increase in 5mC [13]. Differen-
tiation of embryoid bodies is grossly impaired with a lack 
of mesoderm and endoderm markers. Global knockdown 
of all three TET molecules identified 1072 downregulated 
genes and 729 upregulated genes, illustrating that TET 
proteins can activate or repress transcription [13]. Fur-
thermore, reprogramming of fibroblasts into iPSC results 
in increased levels of TET1 and TET2 and a decrease in 
TET3 [14].
Bone marrow mesenchymal stem/stromal cells 
(BMSC) exhibit the capacity for multi-lineage differen-
tiation and self-renewal [15–19]. BMSC maintenance 
and cell fate determination have previously been shown 
to be mediated, in part, by the activity of the histone 3 
lysine 4 (H3K4) methyltransferase, MLL1/2 [20], the 
H3K27 methyltransferase, Ezh2 [21], and associated 
demethylases, KDM6A [21] and KDM6B [22–24], via the 
regulation of key lineage-associated transcription fac-
tors [25–27]. In an effort to further identify epigenetic 
enzymes involved in BMSC lineage determination and 
growth, we examined the function of TET DNA hydrox-
ymethylases in human BMSC lineage determination. 
Previous studies have shown that TET1 can influence 
recruitment of Ezh2 to promoters [28], and plays a role 
in stem cell self renewal. In this study, we have identified 
a function role for both TET1 and TET2 in regulating 
human BMSC differentiation, by acting on genes involved 
in lineage determination. Moreover, we discovered that 
the expression of TET1 and TET2 is grossly deregulated 
in osteoporosis leading to deregulated 5hmC levels on 
promoters of genes controlling stem cell renewal and lin-
eage determination in osteoporosis.
Materials and methods
Cell culture and antibodies
Human BMSC were derived from bone marrow aspirates 
from posterior iliac crest of normal adult volunteers after 
obtaining informed consent according to procedures 
approved by the Human Ethics Committee of the Royal 
Adelaide Hospital, South Australia (protocol# 940911a). 
Immunoselected STRO-1+ BMSC were cultured in regu-
lar growth medium as previously described [29].
In vitro differentiation assays
Human BMSC were cultured in either normal growth 
conditions, osteogenic inductive conditions (control 
growth media + 10−7M dexamethasone, 10  mM HEPES 
buffer and 2.6 mM potassium phosphate) or adipogenic 
inductive conditions (control growth media + 0.5  mM, 
methylisobutylmethylxanthine, 0.5  μM hydrocortisone 
and 60 μM indomethacin) for up to 28 days as previously 
described [18]. Mineralised bone matrix formation was 
identified with Alizarin red (Sigma Aldrich Inc.) stain-
ing [29]. Extracellular calcium was measured in triplicate 
samples and normalised to DNA content per well as pre-
viously described [29]. Lipid formation was assessed and 
quantitation of lipid was performed by Nile red (Sigma 
Aldrich Inc, St Louis, MO) fluorescence staining, nor-
malised to DAPI (Invitrogen/Life Technologies Australia, 
Mulgrave, VIC, AUS) stained nuclei per field of view in 
triplicate wells as previously described [29, 30].
Lentiviral transduction
Lentiviral transductions were performed by transfecting 
5  μg of Lv105 (cat:Ex-Neg-Lv105; Geneocoepia, Rock-
ville, MD), Lv105-TET2 [10], Lv231 (Ex-Neg-Lv231), 
Lv231-TET1 (Ex-E2856-Lv231) into HEK293 T cells 
together with 5 μg of packaging vector psPAX2 and VsVG 
using lipofectamine 2000 (Life Technologies, Carlsbad, 
CA). After 48  h, 5 × 104 BMSC were infected with the 
supernatant for the HEK293 T cells three times every 
12 h in the presence of 4 mg/ml polybrene. Transduced 
BMSC were selected with 1 μg/ml puromycin for 7 days 
and then maintained in 200 ng/ml puromycin.
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siRNA knockdown
BMSC were transfected with 12  pmol siRNA targeting 
either TET1 (s37193; Ambion, Foster City, California), 
TET2 (cat: s29443), TET3 (s47238) or scramble control 
siRNA (AM4613), with RNAiMax lipofectamine (56532) 
in 100  μl media without foetal calf serum for 20  min. 
After 72 h, the media were replaced with either control 
growth media, osteogenic or adipogenic inductive media 
[29, 31, 32].
RNA extractions, cDNA synthesis and real‑time PCR
Total RNA from approximately 1.5 × 105 human BMSC 
was isolated using Trizol (Invitrogen, Grand Island, NY) 
according to manufacturers’ instructions. cDNA and 
real-time PCR was performed as previously described in 
triplicate [32]. Changes in gene expression were calcu-
lated relative to β-actin using the  2−dCT method.
Oligonucleotides and primers
Real‑time primers
β-ACTIN, F: 5′gatcattgctcctcctgagc3′, R: 5′gtcatagtccgc 
ctagaagcat3′. PPARγ2, F: 5′ctcctattgacccagaaagc3′, R: 
5′tcaaaggagtgggagtggtc3′; ADIPSIN, F: 5′gacaccatcgac 
cacgac3′, R: 5′ccacgtcgcagagagttc3′. C/EBPα, F: 5′gggcaa 
ggccaagaagtc3′; R: 5′ttgtcactggtcagctccag3′. LEPTIN, F: 
5′gaaccctgtgcggattcttgt3′; R: 5′tccatcttggataaggtcaggat3′. 
RUNX2, F: 5′gtggacgaggcaagagtttca-3′, R: 5′catcaagcttct 
gtctgtgcc3′. OSTEOPONTIN, F: 5′acatccagtaccctgatgc 
tacag3′, R: 5′gtgggtttcagcactctggt3′. OSTEOCALCIN, 
F: 5′atgagagccctcacactcctcg3′, R: 5′gtcagccaactcgtcacag 
tcc3′. TET1, F: 5′gcagcgtacaggccaccact3′; R: 5′agccggtcgg 
ccattggaag3′. TET2, F: 5′ttcgcagaagcagcagtgaagag3′; R: 
5′agccagagacagcgggattcctt3′. TET3, F: 5′gacgagaacatcggc 
ggcgt3′; R: 5′gtggcagcggttgggcttct3′.
ChIP primers
RUNX2 TSS F: 5′aggccttaccacaagccttt3′, R: 5′agaaagtttgc 
accgcactt3′; RUNX2 Exon F: 5′gcaaaatgagcgacgtgag3′, R: 
5′acaggaagttggggctgtc3′; RUNX2 Intron F: 5′cgattcaag 
agctgctcaca3′, R: 5′cctgttttgccgtcaatttt3′; RUNX2 UTR 
F: 5′tttgcactgggtcatgtgtt3′, R: 5′tggctgcattgaaaagactg3′; 
BMP2 TSS F: 5′atgcggagcacctactgc3′, R: 5′ccgcatcactctgc 
cttact3′; BMP2 Exon F: 5′cttctagcgttgctgcttcc3′, R: 5′agtg 
cctgcgatacaggtct3′; BMP2 Intron F: 5′aaacaggccaaacaca 
gtcc3′, R: 5′agccagggtctcagaacaga3′; BMP2 UTR F: 5′tgc 
aggaaagtgaatgatgg3′, R: 5′tgcataattttgctgcgtgt3′; PPARγ 
TSS F: 5′agcaaacgacaccaggtagc3′, R: 5′ggcacccgtactctgac 
ct3′; PPARγ Exon F: 5′gctgtgcaggagatcacaga3′, R: 5′gggctcc 
ataaagtcaccaa3′; PPARγ Intron F: 5′tcctctccagcgtctgtttt3′, 
R: 5′cccatctgacaaagggctaa3′; PPARγ UTR F: 5′cacagatcc 
accgtttcctt3′, R: 5′acacggtgaaaccctgtctc3′; ADIPSIN TSS 
F: 5′cctccaccctcataaaagca3′, R: 5′gcgttcagagccttccatta3′; 
ADIPSIN Exon F: 5′ctggggcatagtcaaccac3′, R: 5′atcaag 
cgctcggtgatg3′; ADIPSIN Intron F: 5′ggaagagaaggggtcct 
gag3′, R: 5′tccaagccctttccagtatg3′; ADIPSIN UTR F: 5′tcag 
gagttcgagatcagca3′, R: 5′ctacaagcacccacctccat3′.
Chromatin immunoprecipitation (ChIP)
Cultured human BMSC were used for ChIP using the 
Magna ChIP kit (Millipore Corporation, Billerica, MA) 
according to manufacturers’ instructions using 2  μg of 
TET1 (MABE 1034; Millipore Corporation) or 1  μg of 
TET2 (MABE 462) antibody. Purified DNA was then 
analysed by qPCR as previously described [33].
hMeDIP assay
Human BMSC were cultured in normal growth media or 
in osteogenic inductive media for 1 week. Genomic DNA 
was prepared using the Qiagen genomic DNA isolation 
kit and then sonicated to generate 200–500  bp frag-
ments. DNA was denatured in 10 mM Tris–HCl, 1 mM 
EDTA, pH 7.5 (TE buffer), for 10 min at 98  °C and then 
chilled on ice. 1% of denatured DNA was retained as the 
input control. Denatured 5hmC DNA was immunopre-
cipitated for 2 h at 4 °C with 2 μg of monoclonal antibody 
against 5hmC (Ab106918; Abcam, Cambridge, UK) in a 
final volume of 500  μl IP buffer (10  mM sodium phos-
phate (pH 7.0), 140 mM NaCl, 0.05% Triton X-100). The 
immunoprecipitation was incubated with magnetic IgG 
beads for 2 h at 4 °C and washed with IP buffer and then 
in high salt buffer (10  mM sodium phosphate (pH 7.0), 
400  mM NaCl, 0.05% Triton X-100). Immunoprecipi-
tated bead–DNA complex was treated with proteinase 
K for 3 h at 50  °C in elution buffer and hydroxymethyl-
ated DNA purified by using the Qiagen PCR clean-up kit 
(Qiaquick). DNA was quantitated using qPCR.
Global 5hmc and 5mc analysis
The levels of 5mc and 5hmc were assayed by ELISA using 
either the Quest 5-hmc DNA ELISA Kit (Cat# D5425, 
Zymo Research) or 5-mc DNA ELISA Kit (cat# D5325, 
Zymo Research), respectively. Briefly, 96 well plates were 
coated with either anti-5-hydroxymethylcytosine poly-
clonal antibody or anti-5-methylcytosine polyclonal anti-
body (Zymo Research) (1  ng/μl) in coating buffer. BMSC 
were cultured for 2  weeks under normal, osteogenic or 
adipogenic inductive conditions. 100 ng of denatured DNA 
and standard DNA with known 5hmc or 5mc concentra-
tions was added to the wells and incubated for 1 h. After 
washing, the cells were incubated with anti-DNA HRP con-
jugated antibody for 30 min. Wells were washed and HRP 
developer was added. The plates were read at 415 nm.
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Ovariectomised mouse model
Animal experiments and analyses were approved by 
the SA Pathology (23/11) and University of Adelaide 
(M-2013-144) Animal Ethics Committees. Twelve-week-
old C57BL/6 female mice were anesthetised, and then 
their ovaries were either sited (sham surgery) or ovariec-
tomised (OVX) as previously described [34]. The dor-
sal skin was then sutured and the mice were allowed to 
recover under normal housing conditions, with food and 
water provided ad libitum.
Three-dimensional micro-computed tomography 
(µCT) was performed as previously outlined [35] using 
Micro-CT (Skyscan 1076 X-ray Microtomography Sky-
Scan, Bruker MicroCT, Kontich, Belgium, http://bruke 
r-micro ct.com). Briefly, femora isolated from sham and 
OVX mice were scanned at 9 µm resolution, Al 0.5 mm 
filter, excitation 5890 ms, voltage 48 kV, current 110 mA, 
rotation step 0.6 and two-frame averaging. NRecon soft-
ware was used to reconstruct the femora.
The incidence of murine clonogenic osteogenic pro-
genitor cells was assessed using single-cell suspensions 
derived from bone marrow, and collagenase-treated 
crushed femoral bone chips were plated in colony-form-
ing unit-fibroblast assays (CFU-F) which were performed 
as described previously [36].
Immunohistological staining was performed on sec-
tions (5 μm) of paraffin-embedded femora from OVX or 
sham surgery mice blocked using 5% horse serum (PIRL/
SAHMRI; Gilles Plains, SA, Australia). Citrate antigen 
retrieval (DAKO; Glostrup, Denmark) was performed 
for 20 min at 95 °C, and endogenous peroxidase activity 
was quenched using 0.5%  H2O2 in methanol for 40 min 
in the dark. IHC staining was performed using primary 
anti-5hmC antibody (Abcam; Cambridge, UK; 1/500 
dilution), secondary biotinylated anti-rabbit IgG (Vector 
Labs; Burlingame, CA, USA; 1/250 dilution) and tertiary 
streptavidin conjugate (Life Technologies; Carlsbad, CA, 
USA; 1/100 dilution). Sections were stained using Liquid 
 DAB+ Substrate Chromogen System (DAKO) and coun-
terstained in Mayer’s haematoxylin.
Statistics
Data analysis, graph generation and statistical analysis 
were carried out using Microsoft graphpad prism 6. Dif-
ferentiation, ChIP assays and gene expression analysis 
were assessed by one-way ANOVA. Statistical differences 
(*) of p ≤ 0.05 between samples are shown.
Results
BMSC differentiation is dependent on DNA methylation
DNA methylation has been shown to regulate differentia-
tion in many cell types including BMSC. Our initial stud-
ies attempted to verify the repressive function of DNA 
methylation in BMSC lineage determination. Human 
BMSC were cultured in the presence of the DNA methyl 
transferase inhibitor, 5 azacytidine (5Aza-2). Concentra-
tions of 5Aza-2 greater than 2 μM were found to inhibit 
proliferation and induce cell death, and hence all func-
tional experiments were performed with 2  μM 5Aza-2 
(unpublished observations). BMSC cultured in the pres-
ence of 5Aza-2 under osteogenic inductive conditions 
produced larger aggregates of Alizarin red stained min-
eralised deposits, when compared to BMSC treated with 
vehicle alone (Fig. 1a). Moreover, 5Aza-2-treated BMSC 
exhibited significantly higher levels of extracellular cal-
cium when normalised to DNA content per well, com-
pared to vehicle-treated cells. Parallel studies found that 
BMSC treated with 5Aza2 under adipogenic inductive 
conditions resulted in increased numbers of Nile red-
positive lipid-forming adipocytes compared to BMSC 
treated with the vehicle control (Fig.  1b). These results 
confirm that DNA methylation is inhibitory to BMSC 
differentiation.
The role of hydroxymethylation during BMSC 
differentiation
Since DNA methylation is inhibitory to BMSC develop-
ment and the enzymatic activity of TET family proteins 
results in the hydroxylation of methylated DNA (5mC) to 
5hmC, which opposes the repressive functions associated 
(See figure on next page.)
Fig. 1 DNA demethylation promotes BMSC differentiation. a Cultured BMSC were treated with 2 μM 5-Azacytidine-2 (5-Aza2) or vehicle control 
(Veh) under osteogenic inductive conditions for 3 weeks. Mineralised deposits were stained with Alizarin red, and extracellular calcium levels 
were measured normalised to DNA content per well. b Cultured BMSC were treated with 5-Aza or Veh under adipogenic inductive conditions for 
3 weeks. Lipid formation was assessed by Nile red staining, and the number of adipocytes was expressed as a percentage relative to total  DAPI+ 
cells. Data represent n = 3 BMSC donors, *p < 0.05, Students t test. c–e BMSC cultured under osteogenic inductive (Osteo) or normal growth (Cont) 
conditions for 1 to 3 weeks and then analysed by qPCR to assess c TET1, d TET2 and e TET3 gene expression levels, relative to β-actin. f–h BMSC 
cultured under adipogenic inductive (Adipo) or Cont conditions for 1 to 3 weeks and then analysed by qPCR to assess f TET1, g TET2 and h TET3 
gene expression levels relative to β-actin. Data represent mean S.E.M, n = 3 BMSC donors, *p < 0.05, one-way ANOVA with multiple comparison 
analyses. Human BMSC were cultured in Cont media or under Osteo or Adipo inductive conditions for 1 week. Genomic DNA was purified and 
global levels of i 5hmC and j 5mC were measured using by ELISA relative to total input DNA. Data represent n = 3 BMSC donors, *p < 0.05, Students 
t test. k Human BMSC were cultured under Cont, Osteo or Adipo inductive conditions for 2 weeks and then analysed by Western blot to assess TET1 
and TET2 protein levels compared to Raptor as loading control
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with 5mC, we investigated whether the DNA hydroxylase 
TET family of enzymes regulate differentiation of BMSC. 
Analysis of TET1, TET2 and TET3 gene expression dur-
ing BMSC differentiation showed that TET1 transcript 
levels were significantly decreased at 2 and 3 weeks post-
osteogenic induction, when compared to BMSC cultured 
under normal growth conditions (Fig.  1c). In contrast, 
TET2 transcript levels were significantly increased at 
2  weeks post-osteogenic induction (Fig.  1d) and then 
transcript levels decreased. TET3 expression levels only 
showed a significant increase at 4  weeks of osteogenic 
induction compared to control-treated cells (Fig.  1e). 
Gene expression levels measured during adipogenic dif-
ferentiation demonstrated that TET1 transcript levels 
did not significantly change compared to BMSC cul-
tured under normal growth conditions (Fig.  1f ). Levels 
of TET2 transcript did not show any significant changes 
during adipogenesis (Fig.  1g), whereas TET3 showed a 
significant decrease at 1-week post-adipogenic induc-
tion (Fig.  1h). These data suggest that TET molecules 
may play a role in BMSC cell fate determination with 
more dynamic changes in gene expression evident during 
osteogenesis.
Given that 5hmc is an intermediate that leads to DNA 
demethylation and that we saw effects on BMSC differen-
tiation when using the DNA methyltransferase inhibitor, 
we next assessed global levels of 5mc and 5hmc following 
osteogenic and adipogenic induction. The data showed 
a significant increase in 5hmc levels under osteogenic 
conditions for 1  week, with an associated downregula-
tion of 5mc levels (Fig. 1i). Similarly, global 5hmc levels 
appeared elevated correlating with decreased 5mc lev-
els post-1  week under adipogenic inductive conditions 
(Fig.  1j). Western blot analysis revealed that TET1 pro-
tein levels were relatively unchanged during BMSC dif-
ferentiation, while TET2 protein levels were elevated 
following 2 weeks of osteogenic or adipogenic inductive 
conditions (Fig. 1k).
To address the potential role of TET molecules dur-
ing BMSC differentiation, human BMSC were treated 
with either scramble control siRNA or siRNA specific to 
TET1, TET2 or TET3. The gene expression levels of all 
three TET molecules were significantly knocked down 
compared to scrambled controls (Fig.  2a). These results 
were confirmed with two siRNAs directed to either 
TET1, 2 or 3 (data not shown). Western blot analysis con-
firmed diminished TET protein levels following siRNA-
mediated knockdown of TET1, TET2 and TET3 (Fig. 2b).
Functional studies showed that siRNA TET1-treated 
BMSC exhibited an enhanced osteogenic potential, com-
pared to scramble siRNA-treated cells (Fig. 2c), whereas 
siRNA knockdown of TET2 resulted in a significantly 
reduced osteogenic potential, as assessed by Alizarin 
red staining (Fig.  2c) and quantitation of extracellular 
calcium levels (Fig. 2d). However, siRNA knockdown of 
TET3 showed no significant difference in mineral forma-
tion compared to scramble siRNA control cells (Fig. 2c, 
d). Supportive studies found that siRNA TET1-treated 
BMSC expressed significantly higher transcript levels of 
the osteogenic genes RUNX2, BMP-2, but not OSTEO-
PONTIN and OSTEOCALCIN compared to scramble 
siRNA-treated cells, whereas siRNA TET2-treated cells 
displayed a significant reduction in RUNX2, BMP-2, 
OSTEOPONTIN and OSTEOCALCIN gene expression 
levels (Fig. 2e).
Assessment of the role of TET proteins during BMSC 
adipogenic differentiation showed that siRNA knock-
down of TET1 resulted in an increase in Nile red-positive 
adipocytes, compared to the scramble siRNA control 
(Fig.  2f, g). Conversely, siRNA knockdown of TET2 
resulted in a substantial decrease in Nile red-positive 
adipocytes compared to the scramble siRNA-treated 
cells (Fig.  2f, g). However, siRNA knockdown of TET3 
showed no significant effect when compared to scram-
ble siRNA-treated BMSC. Gene expression studies found 
that siRNA TET2-treated BMSC expressed significantly 
lower transcript levels of the adipogenic genes PPARγ2, 
C/EBPα, ADIPSIN and LEPTIN compared to scramble 
siRNA-treated cells (Fig.  2h) with no significant effect 
seen when TET1 or TET3 was knocked down.
The function of TET1 and TET2 during BMSC dif-
ferentiation was confirmed by enforced expression of 
either TET1 or TET2 full-length cDNA in BMSC and 
compared to empty vector controls. Lentiviral-mediated 
Fig. 2 TET1 and TET2 knockdown differentially regulated BMSC differentiation. Cultured BMSC were transfected with siRNA targeting either TET1 
(siTET1), TET2 (siTET2), TET3 (siTET3) or scramble control siRNA (siScram). a Knockdown efficiency was analysed by qPCR relative to β-actin. b 
Knockdown of TET1, TET2 and TET3 protein levels by two siRNA per molecule was analysed by Western blot, using Raptor and Hsp90 protein as 
loading controls. c BMSC cultured under osteogenic inductive conditions were transfected with siTET1, siTET2, siTET3 or siScram. Representative 
images depict levels of Alizarin red-stained mineral deposits. d Extracellular calcium levels were measured and then normalised to DNA content per 
well. e Analysis of RUNX2, BMP2, OSTEOPONTIN (OPN) and OSTEOCALCIN (OCN) gene expression levels was assessed by qPCR per condition, relative 
to β-actin. f BMSC cultured under adipogenic inductive conditions were transfected with siTET1, siTET2, siTET3 or siScram. Representative images 
depict levels of Nile red-stained lipid droplets. g The number of adipocytes was expressed as a percentage relative to total DAPI-positive cells per 
unit area. h Analysis of PPARγ2, C/EBPα, ADIPSIN and LEPTIN gene expression levels was assessed by qPCR per condition, relative to β-actin. Data 
represent mean S.E.M., n = 3 BMSC donors, *p ≤ 0.05 One-way ANOVA with multiple comparison analyses
(See figure on next page.)
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overexpression of TET1 and TET2 was verified using 
qPCR (Fig. 3a) and Western blot analyses (Fig. 3b). Sta-
bly transduced BMSC were subsequently cultured under 
osteogenic inductive conditions and assessed for mineral 
formation. TET1-overexpressing BMSC produced lower 
amounts of Alizarin red mineralised deposits compared 
to empty vector control BMSC, correlating with signifi-
cantly lower extracellular calcium levels (Fig.  3c). Gene 
expression studies found that TET1-overexpressing 
BMSC exhibited lower transcript levels of RUNX2 and 
BMP-2 under osteogenic inductive conditions com-
pared to vector control BMSC (Fig.  3d). In contrast, 
TET2-overexpressing BMSC exhibited greater amounts 
of Alizarin red stained mineralised deposits, correlating 
with significantly higher levels of extracellular calcium 
levels (Fig.  3e). Confirmatory qPCR showed that TET2-
overexpressing BMSC expressed significantly higher lev-
els of RUNX2 and BMP-2 transcripts under osteogenic 
inductive conditions compared to vector control BMSC 
(Fig. 3f ).
We next sought to determine the contribution of both 
TET1 and TET2 to global 5hmC and 5mC demethyla-
tion. Human BMSC were transfected with either siRNA 
targeting TET1 or TET2 alone or both TET1/TET2 in 
combination and then cultured under control or osteo-
genic inductive media. The data showed significant 
effects on global 5hmc levels only when both TET1 and 
TET2 were knocked down in combination under normal 
and osteogenic conditions (Additional file 1: Figure S1a). 
Examination of 5mC revealed that dual knockdown of 
both TET1 and TET2 caused significantly higher levels 
of global 5mC under both normal and osteogenic condi-
tions (Additional file  1: Figure  S1a). Functional analyses 
found that osteogenesis was impeded in the presence of 
siRNA targeting TET2, negating the increase in BMSC 
mineralisation following treatment with siTET1 (Addi-
tional file 1: Figure S1c). Therefore, both TET1 and TET2 
appear to contribute to global 5hmC and 5mC demethyl-
ation but work through different mechanisms to regulate 
BMSC osteogenic differentiation.
Under adipogenic inductive conditions, overexpres-
sion of TET1 inhibited the amount of Nile red-positive, 
lipid-containing adipocytes compared to BMSC infected 
with empty vector (Fig.  3g). Gene expression analyses 
demonstrated significantly lower levels of PPARγ2 and 
transcript in TET1-overexpressing BMSC cultured under 
adipogenic inductive conditions compared to vector con-
trol BMSC (Fig. 3h). Conversely, overexpression of TET2 
promoted higher numbers of lipid-forming adipocytes 
compared to vector control BMSC (Fig.  3i). Supportive 
studies showed that TET2-overexpressing BMSC exhib-
ited significantly higher levels of PPARγ2 and ADIPSIN 
under adipogenic inductive conditions, compared to vec-
tor control BMSC (Fig.  3j). Collectively, these findings 
indicate that TET1 represses differentiation of BMSC 
into osteoblasts or adipocytes and that TET2 promotes 
BMSC differentiation.
Deregulation of TET1 and TET2 expression and activity 
during osteoporosis
During the process of skeletal aging and the development 
of diseases such as age-related osteoporosis, BMSC num-
bers and differentiation potential can be compromised, 
leading to increased adipogenesis in the bone marrow 
at the expense of bone formation [37]. As our results 
clearly show a function for TET molecules in BMSC line-
age determination, we performed experiments to assess 
the levels of TET genes and 5hmC during osteoporosis. 
Femora harvested from mice 12-week post-ovariectomy 
showed reduced levels of trabeculae bone and per cent 
bone relative to tissue volume by μCT analysis, compared 
to aged matched sham surgery controls (Fig.  4a). These 
data correlated with lower numbers of colony-form-
ing units-fibroblastic (CFU-F) in overiectomised mice 
(See figure on next page.)
Fig. 3 Overexpression of TET1 and TET2 differentially regulates osteogenesis and adipogenesis. a BMSC donors were infected with empty lentiviral 
vector alone (Vector), or vector overexpressing TET1 cDNA (TET1OE) or TET2 cDNA (TET2OE). Gene expression levels were analysed by qPCR relative 
to β-actin. b Protein levels of TET1 and TET2 were analysed by Western blot, using Raptor protein as a loading control. c TET1-overexpressing 
BMSC were cultured under osteogenic (Osteo) inductive conditions control media (Cont) for 3 weeks. Representative images depict mineralised 
deposits stained using Alizarin red. Extracellular calcium levels were measured and then normalised to DNA content per well. d Analysis of RUNX2 
and BMP2 gene expression levels was assessed by qPCR per condition, relative to β-actin. e TET2-overexpressing BMSC were cultured under 
Osteo or Cont media for 3 weeks. Representative images depict mineralised deposits stained with Alizarin red. Extracellular calcium levels were 
normalised to DNA content per well. f Analysis of RUNX2 and BMP2 gene expression levels was assessed by qPCR per condition, relative to β-actin. 
g TET1-overexpressing BMSC were cultured under adipogenic (Adipo) inductive conditions or Cont media for 3 weeks. Representative images 
depict levels of Nile red-stained lipid droplets. The number of adipocytes was expressed as a percentage relative to total DAPI positive cells per 
unit area. h Analysis of PPARγ2 and ADIPSIN gene expression levels was assessed by qPCR per condition, relative to β-actin. i TET2-overexpressing 
BMSC were cultured under Adipo or Cont media for 3 weeks. Representative images depict levels of Nile red-stained lipid droplets. The number of 
adipocytes was expressed as a percentage relative to total DAPI-positive cells per unit area. j Analysis of PPARγ2 and ADIPSIN gene expression levels 
was assessed by qPCR per condition, relative to β-actin. Data represent mean S.E.M., n = 3 BMSC donors, *p ≤ 0.05, one-way ANOVA with multiple 
comparison analyses
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compared to sham controls (Fig.  4b). Gene expression 
studies of freshly isolated stromal cells (Sca1+/Lin−/
CD31−/CD45−) demonstrated that transcript levels 
for both TET1 and TET2 were significantly reduced in 
ovariectomised mice, whereas TET3 expression showed 
no significant difference, when compared to sham con-
trols (Fig. 4c). In support of the reduced levels of TET1 
and TET2, we also observed a reduced global staining of 
5hmc in femoral sections derived from overiectomised 
mice compared to sham-treated mice (Fig. 4d). Confirm-
atory analyses showed significantly higher levels of global 
5hmC in cultured stromal cells derived from OVX mouse 
limb bone compared to sham surgery control mouse 
bone (Fig. 4e).
TET1 and TET2 are responsible for 5hmC on lineage genes
Given that the TET1 and TET2 enzymes convert 5mC 
on DNA to 5hmC, h-MeDIP analysis was employed to 
determine the 5hmC status of the lineage markers. To 
determine which TET member is responsible for 5hmC 
on lineage genes, we knocked down all three TET 
family members individually and assessed 5hmC on the 
TSS under normal culture conditions. Knockdown of 
both TET1 and TET2 resulted in a significant decrease 
in 5hmC along the RUNX2 TSS, whereas knockdown 
of TET3 had no significant effect (Fig. 5a). Knockdown 
of TET2 significantly reduced 5hmC on the BMP2 TSS 
but knockdown of TET1 or TET3 had no significant 
effect (Fig.  5b). We next examined whether 5hmc lev-
els change during osteogenic differentiation. The data 
demonstrated significant levels of 5hmC on the RUNX2 
TSS, exon and intron, when compared to the IgG con-
trol in both control and osteogenic inductive condi-
tions (Fig. 5c). The same was evident for the BMP2 TSS, 
exon and intron (Fig. 5d).
We next examined 5hmc on adipogenic genes. siRNA 
knockdown of TET1 or TET2 resulted in a signifi-
cant decrease in 5hmC for both PPARγ2 and ADIPSIN, 
whereas TET3 had no effect (Fig.  6a, b).We then exam-
ined levels of 5hmc during adipogenic differentia-
tion. 5hmc was present on the PPARγ2 TSS, exon and 
intron (Fig.  6c), where levels remained constant under 
Fig. 4 Osteoprogenitor cell numbers and TET1/2 gene expression are reduced in osteoporotic bones. Ovariectomy (OVX) or sham surgeries (Sham) 
were performed on 12-week-old C57/BL6 female mice. a Trabeculae in femora harvested 12 weeks post-OVX or Sham treatment analysed by μCT. 
b The number of clonogenic stromal cells (CFU-F) was assessed from bone marrow and crushed femoral bone isolated from OVX or Sham mice, 
12 weeks post-treatment. c Gene expression levels of TET1, TET2 and TET3 normalised to β-actin were measured by qPCR, in stromal cells isolated 
from the femora of OVX or Sham mice, 12 weeks post-treatment. d Immunohistochemical analysis of 5 μM tibial sections stained with anti-5hmC 
antibody, in OVX or Sham mice, 12 weeks post-treatment. 5hmC staining was detected on bone surfaces in primary spongiosa and chondrocytes in 
growth plate region. e Cultured stromal cells derived from the femora of OVX mice and Sham control mice were cultured in normal media, genomic 
DNA was purified and global levels of 5hmC and 5mC were measured by ELISA relative to total input DNA. Data represent mean S.E.M., n = 5 mice 
per condition donors, *p ≤ 0.05, two-tailed Student t test
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Fig. 5 TET1 and TET2 influence 5hmC on osteogenic genes. BMSC were cultured under normal growth conditions and treated with scramble siRNA 
or siRNA directed to TET1 (siTET1) or TET2 (siTET2) and genomic DNA purified and immunoprecipitated using an antibody to 5hmC. Recruitment 
of 5hmC to genomic regions was assessed by the hme-DIP analysis and normalised to the genomic input control. a Relative enrichment of 5hmC 
on RUNX2 transcription start site (TSS) was measured using PCR. b 5hmC on BMP2 TSS was measured as in (a). BMSC were cultured under normal 
growth and genomic DNA purified and immunoprecipitated using an antibody to 5hmC. Recruitment of 5hmc to genomic regions was assessed 
by the hme-DIP analysis and normalised to the genomic input control. c Cells were cultured under normal and osteogenic conditions. Relative 
enrichment of 5hmC on RUNX2 transcription start site (TSS), exon and intron regions. d Relative enrichment of 5hmC on BMP2 TSS, exon and intron 
regions, percentage input. Data represent mean S.E.M., n = 3 BMSC donors, *p ≤ 0.05, one-way ANOVA with multiple comparison analyses
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Fig. 6 TET1 and TET2 influence 5hmC on adipogenic genes. BMSC were cultured under normal growth conditions and treated with scramble siRNA 
or siRNA directed to TET1 (siTET1) or TET2 (siTET2) and genomic DNA purified and immunoprecipitated using an antibody to 5hmC. Recruitment 
of 5hmC to genomic regions was assessed by the hme-DIP analysis and normalised to the genomic input control. a Relative enrichment of 5hmC 
on PPARγ transcription start site (TSS) and b ADIPSIN was measured using qPCR. c BMSC were cultured under normal growth (Cont) or adipogenic 
(Adipo) conditions and then processed for chromatin extraction. Relative enrichment of 5hmC on PPARγ2 transcription start site (TSS), exon and 
intron regions. d Relative enrichment of 5hmC on ADIPSIN TSS, exon and intron regions. Data represent mean S.E.M., n = 3 BMSC donors, *p ≤ 0.05, 
one-way ANOVA with multiple comparison analyses
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adipogenic conditions. Similar findings were evident for 
the ADIPSIN TSS, exon and intron (Fig. 6d).
TET1 and TET2 directly bind lineage genes
ChIP analysis was employed to examine whether TET1 
and TET2 directly bind to lineage-specific genes to regu-
late transcription. Assessment of the level of TET1 occu-
pancy along the RUNX2 gene locus found that TET1 was 
enriched on the RUNX2 transcription start site (TSS) 
(Fig. 7a), with similar enrichment along the exon, intron 
and 3′UTR, under normal growth conditions compared 
to Ig control. However, under osteogenic inductive con-
ditions, the levels of TET1 on the RUNX2 gene locus 
decreased dramatically. Significant levels of TET1 were 
also present along the BMP2 TSS (Fig.  7b), exon and 
intron, under normal growth conditions; however, TET1 
binding levels were significantly decreased during osteo-
genesis. Assessment of TET2 occupancy by ChIP analysis 
found significant levels of enrichment along the RUNX2 
TSS (Fig.  7c), exon but not the intron or 3′UTR under 
normal growth conditions compared to the IgG control. 
During osteogenesis, TET2 levels remained the same 
along the RUNX2 TSS (Fig.  7c) and exon but increased 
along the intron, with no significant changes on the UTR. 
TET2 was enriched along the BMP2 TSS under control 
conditions (Fig. 7d), and along the TSS, exon and intron 
of BMP2 under osteogenic conditions.
Occupancy of TET1 and TET2 was also examined on 
adipogenic promoters. The data showed that TET1 was 
not enriched on PPARγ2 or ADIPSIN genes under nor-
mal growth or adipogenic inductive conditions (Fig.  8a, 
b). However, TET2 was found to be recruited to PPARγ2 
TSS and ADIPSIN TSS under normal growth condi-
tions but not the exons and introns. TET2 recruitment 
increased under adipogenic conditions and was present 
along exons and introns (Fig. 8c, d).
We have previously reported that the histone H3K27 
methyl transferase, EZH2, is recruited to osteogenic 
genes, repressing osteogenic gene expression. TET1 has 
been shown to interact with SIN3A, HDAC1 and pro-
mote EZH2 recruitment to promoters. We therefore 
examined whether TET1 or TET2 can recruit these pro-
teins in BMSC to lineage-specific promoters. Cells were 
treated with scramble siRNA or siRNA targeting TET1 or 
TET2 and assessed for recruitment of SIN3A, HDAC and 
EZH2. SIN3A was specifically recruited to the RUNX2 
TSS in scramble-treated cells, and specific recruitment 
was eliminated when TET1 was knocked down but not 
when TET2 was knocked down. No specific recruitment 
of HDAC was evident (Fig.  9a). EZH2 was recruited on 
the RUNX2 TSS, which was reduced when TET1 was 
knocked down but not when TET2 was knocked down. A 
similar profile was evident for BMP2. SIN3A and EZH2 
were recruited to the BMP2 TSS. This was drastically 
reduced when TET1 was knocked down but not TET2 
(Fig. 9b). Furthermore, we failed to observe any specific 
recruitment of SIN3A, HDAC or EZH2 on adipogenic 
genes, PPARγ and ADIPSIN (Fig. 9c, d).
Discussion
In this study, we confirmed that inhibition of DNA meth-
ylation promotes human BMSC differentiation as treat-
ment with 5-Aza2 showed increased osteogenesis and 
adipogenesis. This prompted us to examine the impor-
tance of 5hmc in BMSC differentiation, which has been 
shown to counteract the effects of DNA methylation by 
removing the methylation mark or inhibiting further 
methylation. Functional assessment of TET molecules 
found that TET1 inhibits both osteogenesis and adi-
pogenesis by repressing transcription of RUNX2 and 
PPARγ2, two essential master regulators of BMSC oste-
ogenic and adipogenic commitment, respectively. Even 
though TET2 is the main enzyme responsible for 5hmC 
on osteogenic and adipogenic genes, we found that TET1 
is also partly responsible for 5hmC directly on osteogenic 
and indirectly on adipogenic genes as we did not detect 
recruitment of TET1 on adipogenic genes. However, 
TET2 was recruited on the adipogenic genes; hence, it is 
likely that TET1 possibly is in a complex with TET2 or 
it influences the recruitment of TET2 to the adipogenic 
genes.
Functionally, however, TET1 represses transcription of 
osteogenic and adipogenic genes, which conflicts with its 
ability to influence 5hmC. Further analysis revealed that 
TET1 influences the recruitment of SIN3A and EZH2 to 
the osteogenic promoters. This was not evident for TET2. 
We attribute the repressive function of TET1 to its abil-
ity to promote recruitment of the repressors, SIN3A and 
EZH2, to osteogenic genes. We showed that TET1 and 
not TET2 is responsible for their recruitment. Previous 
(See figure on next page.)
Fig. 7 TET1 and TET2 differentially bind to osteogenic gene regions. BMSC were cultured under normal growth (Cont) or osteogenic (Osteo) 
conditions and then processed for chromatin extraction. Recruitment of TET molecules to genomic regions was assessed by chromatin 
immunoprecipitation and normalised to the genomic input control. a Relative enrichment of TET1 on RUNX2 transcription start site (TSS), exon, 
intron and 3′ untranslated region (UTR). b Relative enrichment of TET1 on BMP2 TSS, exon and intron regions. c Relative enrichment of TET2 on 
RUNX2 TSS, exon, intron and UTR. d Relative enrichment of TET2 on BMP2 TSS, exon and intron regions. Data represent mean S.E.M., n = 3 BMSC 
donors, *p ≤ 0.05, one-way ANOVA with multiple comparison analyses
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studies have reported that TET1 can exist in a complex 
with Sin3A and HDAC, recruiting them to promoters 
to influence the recruitment of Ezh2 [28, 38–40]. This is 
consistent with our previous findings showing that Ezh2 
is recruited to osteogenic genes and inhibits osteogenesis 
[21]. This finding therefore has provided some insight 
into how Ezh2 is recruited to the promoters of osteogenic 
genes.
We previously did not detect Ezh2 on adipogenic genes 
nor have we now found TET1 to be recruited. It is likely 
that TET1 is repressing an upstream activator of adi-
pogenesis, and this will be the basis of future investiga-
tions. Secondly, despite the reduction in 5hmC when 
TET1 is knocked down, the increase in gene expression 
and osteogenic and adipogenic differentiation indicates 
that its repressive function is the most prominent feature 
in relation to differentiation. TET1 genomic location in 
ESC has been shown to overlap with PRC2, Ezh2, Sin3A 
and H3K27me3, where it can be recruited by the PRC2 
complex to bivalent sites. TET1 has also been found to 
co-immunoprecipitate with PRC2 complex proteins, 
Ezh2 and SUZ12c. It was reported that with TET1-
dependent demethylation and Ezh2-mediated repres-
sion through Ezh2, the TET1–PRC2 complex maintains 
developmental genes in a poised state of activation and 
is thought to contribute to plasticity [38]. Genome-wide 
studies show that TET1 has a preference to bind gene-
rich regions with CpG-rich promoters with highest levels 
of recruitment along the transcription start sites and less 
so throughout the gene body [41]. A majority of TET1-
bound promoters are also marked with H3K4me3, high 
CpG content which are hypomethylated in support of 
the role of TET1 in removing DNA methylation [42]. A 
second set of TET1-bound genes was associated with 
H3K27me3 and corresponded to the binding of the PRC2 
complex [43]. A significant amount of these genes are 
involved in differentiation and development, with TET1 
associated with H3K27me3 or bivalent domains. 5hmC 
is enriched at promoter regions and TSS and mainly on 
regions enriched in CpG islands, which are devoid of 
5mC implying that TET1 via its ability to hydroxylate 
5mC contributes to the hypomethylated signature of 
CpG islands in ESC [40].
In our study, TET2 was found to promote BMSC cell 
lineage commitment towards either an osteoblast or 
adipocyte fate, partly via transcriptional activation of 
Runx2 or PPARγ2, respectively, and it was the main pro-
tein of the TET family responsible for 5hmC on both 
osteogenic and adipogenic genes. Interestingly, the third 
TET family member, TET3, appeared to have no effect 
on human BMSC differentiation. Our finding that TET1 
is a potential inhibitor of human BMSC differentiation is 
in accord with previous studies identifying a functional 
role for TET1 in ESC, iPSC and neuronal stem cell devel-
opment [44, 45]. TET1-deficient ESC display impaired 
self-renewal capacity, partly because of increased meth-
ylation and decreased expression of Nanog [5]. Another 
study, however, reported that TET1-deficient ESC dis-
played normal levels of pluripotency genes [46]; however, 
studies consistently show an increase in lineage-specific 
markers, such as trophoectoderm and neuroectoderm, 
associated with developmental skewing towards endo-
derm and mesoderm fates [44]. Triple knockout of 
TET1-3 in mESC shows results in an overactive Wnt 
signalling which results in skewed differentiation to mes-
oderm at the expense of neuroectoderm [47]. Wnt signal-
ling is important in osteogenesis and adipogenesis, and 
it would be of interest to determine the effect of TET1–
TET3 on Wnt signalling and differentiation in bone 
marrow-derived MSC. These findings correlate with our 
observations that reduction of TET1 expression resulted 
in an increase in osteogenesis and adipogenesis, while 
overexpression of TET1 inhibited BMSC differentiation.
In agreement, with our data a recent study found that 
TET2 is mainly responsible for inducing adipogenesis of 
a murine preadipocyte cell line 3T3-L1 and was respon-
sible for 5hmC of the PPARγ locus [48]. In another study, 
TET2 and TET1 were found to promote osteoblast for-
mation of murine mesenchymal multipotent C3H cells 
using short hairpin RNA. Both TET1 and TET2 were 
found to promote 5hmC [49]. TET2 has been found to 
be responsible for neurogenic differentiation of neuronal 
stem cells and is primarily responsible for the 5hmC 
dynamics [50]. Another study showed that knockdown of 
TET2 but not TET1 inhibited myogenic differentiation of 
myoblasts and was responsible for 5hmC [51]. In agree-
ment, previous studies have found that TET2 is master 
regulator of smooth muscle cell differentiation [10].
In mESC, it has been shown that TET2 knockout 
results in 90% reduction in 5hmC, whereas knockout of 
Fig. 8 TET1 and TET2 differentially bind to adipogenic gene regions. BMSC were cultured under normal growth (Cont) or adipogenic (Adipo) 
conditions and then processed for chromatin extraction. Recruitment of TET molecules to genomic regions was assessed by chromatin 
immunoprecipitation and normalised to the genomic input control. a Relative enrichment of TET1 on PPARγ2 transcription start site (TSS), exon and 
intron regions. b Relative enrichment of TET1 on ADIPSIN TSS, exon and intron regions. c Relative enrichment of TET2 on PPARγ2 TSS, exon and intron 
regions. d Relative enrichment of TET2 on ADIPSIN TSS, exon and intron regions. Data represent mean S.E.M., n = 3 BMSC donors, *p ≤ 0.05, one-way 
ANOVA with multiple comparison analyses
(See figure on next page.)
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TET1 results in 44% reduction.  TET2−/− mESC showed 
delayed gene transcription kinetics during ESC differen-
tiation to the neuronal lineage [52]. Although the TET2 
data are in agreement, the TET1 functional data con-
tradict ours. This could be due to TET1 having a differ-
ent function in the murine MSC cell line as opposed to 
primary human MSC. Another study has shown using 
a murine teratocarcinoma cell line, ATDC5, that TET1 
promotes chondrogenesis and 5hmC by short hair pin 
RNA [53]. Similarly, TET1 knockdown using shRNA len-
tiviral vectors shows that TET1 promotes odontogenic 
differentiation of dental pulp stem cells [54]. A recent 
study by Yang et al. found that TET1 and TET2 deficiency 
in mouse bone cells reduced demethylation of the P2rX7 
promoter and thus downregulated exosome release, 
leading to intracellular accumulation of miRNAs which 
inhibits Runx2 signalling to impair osteogenic differen-
tiation [9]. It therefore appears that TET molecules may 
act through direct and indirect mechanisms to regulate 
BMSC cell fate determination.
Our studies revealed the occupancy of TET2 on bone-
associated genes, RUNX2 and BMP2, with TET2 lev-
els increasing during osteogenic induction across exons 
and introns, whereas the appearance of 5hmC remained 
relatively the same, even though TET2 was shown to 
be a transcriptional activator of these genes based on 
knockdown experiments. TET2 knockdown studies 
showed that the presence of 5hmC on osteogenic and 
adipogenic promoters was mainly attributed to TET2. A 
recent study reported that stable expression of the osteo-
blast transcription factor, Osterix, during BMP2-induced 
osteoblast differentiation involved TET-dependent DNA 
demethylation and SWI/SNF-associated nucleosome 
remodelling at the Osterix promoter, in mouse embryonic 
fibroblasts [49]. Therefore, while TET2-mediated conver-
sion of 5mC into 5hmC is needed for transcriptional acti-
vation, this occurs in conjunction with other recruited 
epigenetic enzymes and chromatin remodelling enzymes 
[49]. It is therefore likely that TET2 can interact with 
other enzymes to modify the nucleosomes and increase 
transcription. This is evident in smooth muscle cells, 
where removal of TET2 results in a decrease in chro-
matin accessibility and increased H3K27me3 on Myocd, 
Srf and Myh11 gene loci [10], leading to suppression of 
smooth muscle differentiation. Genome-wide studies of 
TET1 deletion in ESC correlated with diminished 5hmC 
levels and a change in the histone methylation status, 
supporting the notion that TET proteins and 5hmC can 
regulate other nucleosome modifications [43, 55]. When 
considering the gene binding profile of TET1, TET2 and 
5hmC in BMSC, we believe that TET-mediated 5hmC is 
a marker for poised transcription and is present on genes 
that are active or can be transcriptionally activated in 
Fig. 9 TET1 influences SIN3A and EZH2 binding to osteogenic genes. 
a BMSC were treated with scramble siRNA (scram), siTET1 or siTET2, 
cultured under normal growth and then processed for chromatin 
extraction. Recruitment of SIN3A, HDAC2 or EZH2 molecules to the 
RUNX2 transcription start site (RUNX2 TSS) was assessed by chromatin 
immunoprecipitation and normalised to the genomic input control. 
b Cells were treated as in (a) but enrichment was assessed on the 
BMP2 transcription start site (BMP2 TSS). c Cells were treated as in (a) 
but enrichment was assessed on the PPARγ transcription start site 
(PPAR TSS). d Cells were treated as in (a) but enrichment was assessed 
on the ADIPSIN transcription start site (ADIPSIN TSS). Data represent 
mean S.E.M., n = 3 BMSC donors, *p ≤ 0.05, one-way ANOVA with 
multiple comparison analyses
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BMSC. This is supported by other studies showing that 
5hmC is biased towards activated genes involved in dif-
ferentiation [56]. Genome-wide studies have discovered 
that genes with 5hmC at their TSS tend to also be CpG 
rich and contain bivalent domains, and are more likely 
to be upregulated during differentiation; thus, 5hmC is 
likely to contribute to the poised state of activation [57].
While the present study failed to observe any effect 
of TET3 on BMSC differentiation, there may be some 
possibility of redundancy between TET molecules. We 
showed that dual knockdown of both TET1 and TET2 
in human BMSC was required to significantly decrease 
global levels of 5hmC and increase 5mC under either 
normal or osteogenic inductive conditions. However, we 
failed to observe any additive effects of knocking down 
both TET1 and TET2 on BMSC osteogenic differentia-
tion, when compared to TET2 knockdown alone. Similar 
studies examining TET3 knockdown in combination with 
TET2 knockdown showed no significant additive effects 
on BMSC osteogenic differentiation compared to TET2 
alone (data not shown), implying that TET2 has a domi-
nant effect on osteogenesis.
In an attempt to initiate studies examining the func-
tion of TET enzymes during bone disease, we examined 
expression levels of TET molecules in ovariectomised 
osteoporotic mice. The data demonstrated a significant 
decrease in expression of TET1 and TET2 and overall 
5hmC levels in the bones of ovariectomised mice. These 
results strengthen our conclusions that TET1 and TET2 
have important functions in 5hmC and bone biology Their 
concomitant reduction in the murine osteoporotic model 
also suggests that both TET1 and TET2 could have similar 
functions in murine bone marrow stromal cells. A recent 
mouse study showed that depletion of both TET1 and 
TET2 resulted in impaired self-renewal and differentiation 
of BMSC, which was associated with a significant osteo-
penia phenotype and supports the observation that TET1 
and TET2 expression is reduced in OXV mice leading to 
decreased 5hmC levels in BMSC and impaired bone for-
mation [9]. Given that both TET1 and TET2 are severely 
reduced in osteoporosis, pharmacological re-induction of 
TET1/TET2 may be of therapeutic benefit to individuals 
suffering from age-related bone loss or osteoporosis [58].
Conclusion
In summary, TET DNA dioxygenases were found to play 
a critical role in BMSC differentiation. TET1 was found to 
be an inhibitor of BMSC osteogenic and adipogenic differ-
entiation and appeared to act via an indirect mechanism 
through the recruitment of other epigenetic modifiers 
such as SIN3A and EZH2 (Fig. 10). Conversely, TET2 was 
found to directly promote BMSC osteogenic and adipo-
genic differentiation. Moreover, both TET1 and TET2 
transcript levels were shown to be downregulated during 
osteoporosis. Targeting TET molecules or their down-
stream targets may offer new therapeutic strategies to help 
prevent bone loss and repair following trauma or disease. 
Additional file
Additional file 1: Figure S1. TET1 and TET2 contribute to global 
5hmC and 5mC demethylation. (a) Human BMSC were treated with 
siRNA directed to TET1 (siTET1) or TET2 (siTET2) alone or in combina-
tion (siTET1 + 2), then cultured under normal control media or under 
osteogenic inductive conditions for 1 week. Genomic DNA was purified 
and global 5hmC and 5mC levels were measured by ELISA, relative to total 
input DNA. Data represent mean S.E.M, n = 3 BMSC donors, *p < 0.05, one-
way ANOVA with multiple comparisons. (b) BMSC were treated with either 
siTET1 or siTET2 alone or in combination (siTET1 + 2) and then cultured 
under osteogenic inductive conditions for 3 weeks. Mineral deposits were 
stained with Alizarin red.
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Fig. 10 Function of TET1 and TET2 in human MSC lineage 
determination. a 5hmC mark on osteogenic genes is directly 
attributed to TET2 and to some extent TET1 allowing a permissive 
transcriptional state. TET1 also represses osteogenic gene 
transcription presumably by recruiting SIN3A and EZH2, where its 
removal during osteogenesis activates gene transcription. b TET2 
is directly responsible for 5hmC on adipogenic genes, allowing for 
a permissive transcriptional state, where TET1 indirectly represses 
adipogenic gene transcription
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